Tau protein, beta-amyloid(1-42) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33152696" target="_blank" >RIV/61989592:15110/14:33152696 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15310/14:33152696

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S0022510X14003566#" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0022510X14003566#</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jns.2014.05.052" target="_blank" >10.1016/j.jns.2014.05.052</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Tau protein, beta-amyloid(1-42) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia

Popis výsledku v původním jazyce

Background: Parkinson's disease (PD), PD with dementia (PDD) and Lewy body dementia (DLB) are synucleinopathies. PDD and DLB are sometimes considered a transition between PD and Alzheimer dementia (AD). Finding in vivo markers or their combination couldhelp in the differential diagnosis of these neurodegenerative (ND) diseases. Objective: The aim of this study was to assess cerebrospinal fluid (CSF) levels of tau protein, betaamyloid(1-42) and clusterin and to compare these levels among patients with probable PD, PDD, DLB and AD. Methods: CSF levels of ND markers were assessed in 96 patients (27 patients with PD, 14 with PDD, 14 with DLB, 17 with AD and 24 subjects as a control group). Results: In all of the groups of patients, beta-amyloid(1-42) levels were decreasing in the order PD } PDD } DLB } AD, whereas tau protein and the tau protein/beta-amyloid(1-42) index were increasing in the same order (PD { PDD { AD), except for DLB. In paired group comparisons, higher levels of cluster

Název v anglickém jazyce

Tau protein, beta-amyloid(1-42) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia

Popis výsledku anglicky

Background: Parkinson's disease (PD), PD with dementia (PDD) and Lewy body dementia (DLB) are synucleinopathies. PDD and DLB are sometimes considered a transition between PD and Alzheimer dementia (AD). Finding in vivo markers or their combination couldhelp in the differential diagnosis of these neurodegenerative (ND) diseases. Objective: The aim of this study was to assess cerebrospinal fluid (CSF) levels of tau protein, betaamyloid(1-42) and clusterin and to compare these levels among patients with probable PD, PDD, DLB and AD. Methods: CSF levels of ND markers were assessed in 96 patients (27 patients with PD, 14 with PDD, 14 with DLB, 17 with AD and 24 subjects as a control group). Results: In all of the groups of patients, beta-amyloid(1-42) levels were decreasing in the order PD } PDD } DLB } AD, whereas tau protein and the tau protein/beta-amyloid(1-42) index were increasing in the same order (PD { PDD { AD), except for DLB. In paired group comparisons, higher levels of cluster

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

<a href="/cs/project/NT12221" target="_blank" >NT12221: Markery neurodegenerace v diferenciální diagnostice parkinsonských syndromů</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the Neurological Sciences

ISSN

0022-510X

e-ISSN

—

Svazek periodika

343

Číslo periodika v rámci svazku

1-2

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

5

Strana od-do

120-124

Kód UT WoS článku

000340303900024

EID výsledku v databázi Scopus

—